Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.13) by 23.08 percent. This is a 56.52 percent increase over losses of $(0.23) per share from the same period last year.
Related Posts
Truist Securities Maintains Buy on Dine Brands Global, Lowers Price Target to $92
Truist Securities analyst Jake Bartlett maintains Dine Brands Global (NYSE:DIN) with a Buy and lowers the price target from $100 to $92.
Christie Slams DeSantis’ Bud Light Lawsuit: ‘He Wants To Ride That Horse As Hard As He Possibly Can’
Former New Jersey Governor Chris Christie criticized Florida Governor Ron DeSantis' decision to pursue a lawsuit against Anheuser-Busch Inbev SA (NYSE: BUD), the parent company of Bud Light,
Dogness Announces Retail Distribution Partnership With Xiuhu
Dogness Continues to Build Momentum in its Largest Revenue Markets
DONGGUAN, China, July 7, 2022 /PRNewswire/ -- Dogness (International) Corporation ("Dogness" or the "Company")